Afibrinogenemia clinical trials
The registry lists 32 studies for Afibrinogenemia across more than 10 countries. 5 are recruiting or about to start. 24 of them are mainly about Afibrinogenemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-14.
Get an email when these change. Save the Afibrinogenemia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
CSL Behring (4) · Octapharma (4) · University Hospital, Geneva (2) · Biotest (2) · IRCCS Policlinico S. Donato (2) · Weill Medical College of Cornell University (2) · Sunnybrook Health Sciences Centre (1) · University of Sao Paulo General Hospital (1)
What is being tested here
Drugs under test in Afibrinogenemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Homo sapiens whole | 1 | 1 | 1 |
| Fibrinogen | 0 | 2 | 10 |
| Prothrombin complex concentrate | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2, phase 3 first
- Jun 2027Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery · Phase 3 · CSL Behring
- Mar 2027Point of Care Fibrinogen Measurement in Trauma Patients in the Emergency Department · Erasmus Medical Center
Who these studies take
Of the 3 Afibrinogenemia studies recruiting now, 3 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 3 (100%) | 3 (100%) |
Across all 32 studies, recruiting or not: 25% stop at 75 or younger and 16% at 65; 56% take children; 6% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 32 of 32. search them.
- Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated HemorrhageEnrolling by invitationNCT072181851 country
- Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive SurgeryRecruitingNCT06617897Phase 31 country
- Point of Care Fibrinogen Measurement in Trauma Patients in the Emergency DepartmentRecruitingNCT070973371 country
- Individualized Dose of Fibrinogen Following Cardiopulmonary BypassNot yet recruitingNCT074256001 country
- A Point-of-care Electrochemical-based Device for Rapid Detection of Fibrinogen on Type A Aortic Dissection SurgeryRecruitingNCT064343891 country
- Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative BleedingCompletedNCT05711524Phase 41 country
- Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen DeficiencyCompletedNCT02065882Phase 35 countries
- Safety and Efficacy of Fibryga in Congenital Fibrinogen DeficiencyTerminatedNCT037934262 countries
- Adjusted Fibrinogen Replacement StrategyCompletedNCT03444324Phase 37 countries
- Clinical Decision Support for Blood Transfusions to Improve Guideline AdherenceCompletedNCT05634005Not applicable1 country
- Effectiveness of Different Fibrinogen Preparations in Restoring Clot FirmnessCompletedNCT05780125Phase 21 country
- FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical ProphylaxisWithdrawnNCT04636268Phase 3
- Fibrinogen Concentrate (Human) - Efficacy and Safety StudyWithdrawnNCT00916656Phase 3
- Pregnancy and Fibrinogen DisordersCompletedNCT039203323 countries
- Pharmacokinetic Model of Fibrinogen Plasma Levels After Fibrinogen AdministrationCompletedNCT055034981 country
- Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital AfibrinogenemiaCompletedNCT02281500Phase 1/24 countries
- ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac SurgeryTerminatedNCT04434001Phase 21 country
- Human Fibrinogen Concentrate in Pediatric Cardiac SurgeryCompletedNCT02822599Phase 41 country
- Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After SurgeryCompletedNCT02267226Phase 39 countries
- Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen DeficiencyCompletedNCT02408484Phase 33 countries
- Quality of Life in Patients With Congenital AfibrinogenemiaCompletedNCT0348406521 countries
- FIBrinogen REplenishment in SurgeryCompletedNCT03037424Phase 31 country
- Fibrinogen Concentrate In Children Cardiac Surgery 2Status unknownNCT03884725Phase 41 country
- Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative TransfusionsTerminatedNCT02540434Not applicable1 country
- F-Point Validation StudyStatus unknownNCT036230611 country
- Early Administration of Fibrinogen in Polytraumatized Patients With Hypofibrinogenemia: a Randomized Feasibility TrialCompletedNCT02864875Phase 41 country
- Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/RiastapCompletedNCT01575756Phase 26 countries
- An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen DeficiencyCompletedNCT024272172 countries
- Predictors of Hypofibrinogenemia in Severe TraumaCompletedNCT030208491 country
- Human Fibrinogen - PharmacokineticsCompletedNCT00496262Phase 22 countries
- Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)CompletedNCT02203968Phase 1/21 country
- Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen DeficiencyCompletedNCT02094430Phase 2/34 countries